Shukra Pharmaceuticals Ltd

524632·NSE·
0.00 +0.00 (+0.00%)
Market Cap2404.25 Cr
PE Ratio236.05
Volume
Day High - Low
52W High-Low54.90 - 40.06

Shukra Pharmaceuticals Ltd (524632): company summary

Shukra Pharmaceuticals Ltd (524632) is a micro-cap Healthcare company valued at ₹2,404 crore operating in Pharmaceuticals on the NSE and BSE.

Shukra Pharmaceuticals Ltd (524632) is a micro-cap Healthcare company valued at ₹2,404 crore operating in Pharmaceuticals on the NSE and BSE.

Financial performance
Revenue has been shrinking at -1.3% a year over three years; profit grew 70.5% a year, ahead of revenue — margins are expanding. Return on equity is 28.9%.
Valuation multiples
The stock trades at 236.1 times earnings, a premium to the Healthcare median of 32.5, 23.81 times book value. It yields 0.0%.

Generated from DocStoX data. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

Not currently trading — we have seen no trades on NSE or BSE recently. It may be suspended, delisted, or renamed after a corporate action. Not a live price.
DocStoX Score
5.7/10
Fair
Fair Value
Sign in to see
ROE
28.90%
Strong
P/E
236.05x
Expensive
Debt / Equity
0.06
Low
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed

Price performance

52W40.06
54.90
DocStoX take

Supported by growth (10.0) and quality (7.5), but held back by valuation (0.0). Growth looks strong at 10.0, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you. Scored on 4 of 5 measures.

DocStoX score

Medium confidence
5.7
/10
Fair
Quality
Excellent
ROE 28.9%
Valuation
Expensive
P/E 200.0×
Growth
Strong
Revenue +38.8% 5Y CAGR
Risk
Elevated
D/E 0.06
Momentum
No data
No technical indicators

Scored on 4 of 5 measures — the rest have no data for this company.

At a glance

Market Cap
₹2,404 Cr
52W High / Low
₹55 / ₹40
Dividend Yield
0.02%
Promoter Holding
51.15%
EPS (TTM)
₹0.22
Book Value
₹2.18

Key highlights

  • Profit compounding 71% a year
  • Revenue compounding 39% a year
  • Healthy net margin (30%)
  • Valuation is weak (0.0/10)
  • Expensive at 200× earnings
4 Positives2 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Shukra Pharmaceuticals Ltd peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.